Prevention of Future Death Notice – the EPS system does not highlight urgent prescriptions to pharmacies
“The EPS system does NOT allow urgent prescriptions to be highlighted to the receiving pharmacy when sent from a […]
Electronic repeat dispensing toolkit
Electronic repeat dispensing (eRD) is an integral part of EPS, which offers many extra benefits over paper repeat dispensing and repeat prescribing.
NHS Digital have recently published an Electronic Repeat Dispensing Toolkit, available at which contains useful tools. You can also sign up for some eRD webinars to find out more. The toolkit includes an e-learning package, developed by NECS in conjunction with NHS Digital which can also be accessed through the NECS Medicines website.
Antipsychotic prescribing CQUIN
Update on local CQUIN: Initiating antipsychotic treatment and associated monitoring
Out of Stock List December 2015
The following items are currently unavailable, hard to obtain or going short in the market. It is not an exhaustive […]
Clozapine – constipation as an under-recognised life-threatening effect of clozapine
Constipation is an under-recognised life-threatening adverse effect of clozapine.
Clozapine has been associated with varying degrees of impairment of intestinal peristalsis, ranging from constipation to intestinal obstruction, faecal impaction and paralytic ileus. On rare occasions theses cases have been fatal.
Name change of Camcolit 250mg tablets
The proprietary (brand) name of “Camcolit 250mg tablets” has changed to “Lithium Carbonate Essential Pharma 250 mg film-coated tablets”, effective from 1st October 2015.
Controlled Drugs: Learning from Incidents October 2015
NECS supports the NHS England Area Team Controlled Drugs Accountable Officer in ensuring the safe management and use of controlled drugs within the North East & Cumbria region. Based on the commonly reported incidents and the lessons learned, we aim to share good practice across the region.
Mirabegron: risk of severe hypertension and associated cerebrovascular and cardiac events
Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.
Oral bisphosphonates: reminder of precautions to take
All bisphosphonates are associated with a risk of osteonecrosis of the jaw (ONJ). Therefore before prescribing oral bisphosphonates, we remind you to tell patients to maintain good oral hygiene, attend routine dental check-ups and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.